Antithrombotic therapy in patients with atrial fibrillation and acute coronary syndrome in the real world: data from the Berlin AFibACS Registry.

CONCLUSIONS: These data suggest that in AFibACS patients, antithrombotic treatment focussed on dual antiplatelet therapy for ACS, rather than on anticoagulation therapy for stroke prevention. Factors influencing therapy at discharge were age, renal failure, stent implantation, AFib category, and CHA₂DS₂-VASc score. During the study period, triple therapy increased for stented patients. PMID: 24142683 [PubMed - as supplied by publisher]

http://www.ncbi.nlm.nih.gov/pubmed/24142683?dopt=Abstract

Source: Cardiology Journal - October 21, 2013 Category: Cardiology Authors: Maier B, Hegenbarth C, Theres H, Schoeller R, Schühlen H, Behrens S Tags: Cardiol J Source Type: research